Returns
| Series | 1 week | 1 month | 3 months | 6 months | YTD | 1 year | 3 years (ann.) | 5 years (ann.) | 10 years (ann.) | Since inception (ann.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Market-price return | +1.26% | -7.36% | -3.85% | -0.39% | -7.27% | -0.45% | +1.95% | -4.83% | +0.36% | -0.98% |
| Market-price total return | +1.26% | -6.54% | -1.16% | +5.42% | +1.03% | +11.66% | +13.59% | +4.30% | +9.02% | +7.49% |
| NAV return | +1.38% | -4.07% | -3.15% | +4.72% | -0.10% | +4.03% | -1.85% | -4.28% | — | +0.44% |
| NAV total return | +1.38% | -3.25% | -0.56% | +10.77% | +8.81% | +16.58% | +8.94% | +4.43% | — | +8.50% |
Performance through Oct 14, 2026. Price and NAV returns are simple changes; total returns reinvest each distribution at the series value on its ex-date (first observation on/after). Periods of one year or less are cumulative; longer periods are annualised. Series are built from unadjusted prices plus the distribution record so no distribution is counted twice. Corporate actions: the vendor price series is split-adjusted; rights offerings and mergers are not restated — check Corporate Actions.
Growth of $10,000, five years
Risk statistics
| Statistic | Market price | NAV | Specification |
|---|---|---|---|
| Volatility, 1 year | 0.18% | 0.23% | annualised SD of daily total returns, √252 |
| Volatility, 3 years | 0.19% | 0.18% | as above |
| Volatility, 5 years | 0.19% | 0.17% | as above |
| Maximum drawdown, 3 years | -25.83% | -20.85% | peak-to-trough on the total-return index |
| Sharpe ratio, 3 years | 0.53 | 0.33 | excess over FRED DGS3MO (window average) (avg 4.52%), annualised |
| Sortino ratio, 3 years | 0.74 | 0.48 | downside deviation of excess returns |
| Beta vs. benchmark proxy, 3 years | 0.60 | — | SPY (U.S. equity ETF proxy), daily, aligned dates |
| Correlation, 3 years | 0.49 | — | as above |
| Observations (3y) | 751 | — | minimum 60; rankings require 500 |
Market-price and NAV volatility are different quantities and are never mixed. NAV volatility for funds holding stale-marked or illiquid assets can understate economic risk.
CEF Explorer research page for abrdn Healthcare Opportunities Fund. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.